Z
9.30
-0.06 (-0.64%)
| Previous Close | 9.36 |
| Open | 9.42 |
| Volume | 910,952 |
| Avg. Volume (3M) | 1,198,644 |
| Market Cap | 522,056,448 |
| Price / Earnings (Forward) | 8.26 |
| Price / Sales | 8.10 |
| Price / Book | 4.51 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2025 |
| Profit Margin | -226.64% |
| Operating Margin (TTM) | -26.28% |
| Diluted EPS (TTM) | -1.94 |
| Quarterly Revenue Growth (YOY) | 495.70% |
| Total Debt/Equity (MRQ) | 150.74% |
| Current Ratio (MRQ) | 3.02 |
| Operating Cash Flow (TTM) | -61.72 M |
| Levered Free Cash Flow (TTM) | -39.23 M |
| Return on Assets (TTM) | -27.73% |
| Return on Equity (TTM) | -204.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Zevra Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 5.0 |
| Insider Activity | 1.5 |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.69% |
| % Held by Institutions | 65.42% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Velan Capital Investment Management Lp | 30 Jun 2025 | 715,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 29.00 (Cantor Fitzgerald, 211.83%) | Buy |
| Median | 26.00 (179.57%) | |
| Low | 18.00 (JMP Securities, 93.55%) | Buy |
| Average | 24.33 (161.61%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 10.29 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 13 Aug 2025 | 18.00 (93.55%) | Buy | 9.43 |
| Cantor Fitzgerald | 10 Jul 2025 | 29.00 (211.83%) | Buy | 12.02 |
| HC Wainwright & Co. | 02 Jul 2025 | 26.00 (179.57%) | Buy | 9.41 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BODE JOHN B | 9.01 | - | 5,000 | 45,025 |
| Aggregate Net Quantity | 5,000 | |||
| Aggregate Net Value ($) | 45,025 | |||
| Aggregate Avg. Buy ($) | 9.01 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BODE JOHN B | Director | 19 Aug 2025 | Buy (+) | 5,000 | 9.01 | 45,025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |